Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | AZD5991 + AZD8186 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AZD5991 | AZD-5991|AZD 5991 | MCL1 Inhibitor 18 | AZD5991 binds to and inhibits Mcl1, potentially resulting in increased tumor cell apoptosis and decreased tumor growth (Cancer Res July 1 2017 (77) (13 Supplement) DDT01-02, PMID: 32204955). | |
AZD8186 | AZD-8186|AZD 8186 | PIK3CB inhibitor 8 PIK3CD inhibitor 27 | AZD8186 selectively inhibits the activity of PI3Kbeta (PIK3CB) and delta (PIK3CD) in the PI3K/Akt/mTOR signaling pathway, which may result in decreased tumor cell proliferation (PMID: 25514658, PMID: 32194423). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
PTEN inact mut | breast cancer | predicted - sensitive | AZD5991 + AZD8186 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, the combination of AZD5991 and AZD8186 synergistically inhibited proliferation and induced apoptosis in a triple-negative breast cancer cell line and hormone receptor-positive breast cancer cell line each harboring a PTEN inactivating mutation in culture and inhibited tumor growth in cell line xenograft models (PMID: 36241868). | 36241868 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|